Given these unfortunate but not uncommon technical limitations of gene transfer, alternative delivery approaches for DN-TNF should be explored to ensure greater coverage of large anatomical structures like the striatum to unequivocally establish whether neutralization of soluble TNF affords therapeutic benefit in this mouse model of HD. The gene discussed is TNF; the disease is Huntington disease.